

 See the webpage for non-financial data (ESG data).
<https://global.sawai-group.com/holdings/sustainability/esg/>

Financial indicators

(Sawai Group Holdings Co., Ltd. and its subsidiaries)

	Japanese GAAP →			
	FY2013	FY2014	FY2015	FY2016
For the fiscal year (Millions of yen)				
Net sales / Revenue	89,824	105,454	123,492	132,428
Cost of sales	48,353	60,048	71,858	80,309
Gross profit	41,471	45,406	51,634	52,119
Selling, general and administrative expenses/ Selling, general and administrative expenses (including research and development expenses)	22,380	24,718	28,449	31,486
Operating income / Operating profit (loss)	19,091	20,688	23,185	20,633
Profit before income taxes / Profit (loss) before tax	18,990	20,298	23,092	19,871
Profit attributable to owners of parent / Profit (loss) attributable to owners of the Company	12,193	14,053	17,156	15,914
Research and development (R&D) expenses	5,170	6,110	8,019	10,208
Capital expenditures	7,353	13,251	17,775	16,194
Depreciation and amortization	4,989	5,863	7,044	8,645
At fiscal year-end (Millions of yen)				
Total assets	149,348	166,180	206,492	221,539
Inventories	39,182	44,663	55,668	61,777
Total current liabilities	39,097	42,209	50,078	54,876
Total long-term liabilities / Total non-current liabilities	8,949	11,572	30,692	29,063
Net assets/Total equity	101,302	112,399	125,722	137,600
Cash flows (Millions of yen)				
Net cash provided by operating activities/Cash flows from operating activities	13,422	12,112	19,975	20,628
Net cash used in investing activities/Cash flows from investing activities	(8,283)	(14,123)	(22,937)	(16,207)
Net cash provided by (used in) financing activities/Cash flows from financing activities	(178)	(922)	13,473	(6,740)
Cash and cash equivalents at end of year/Cash and cash equivalents at the end of the year	25,537	22,604	33,096	30,771
Financial indicators (%)				
Ratio of R&D expenses to sales/Ratio of research and development expenses to revenue	5.8	5.8	6.5	7.7
Return on equity/Return on equity attributable to owners of the Company	15.0	13.2	14.4	12.1
Shareholders' equity to total assets/ Ratio of equity attributable to owners of the Company to total assets	67.8	67.6	60.8	62.0
Per share information (yen)				
Net income—basic / Basic earnings per share	365.18	382.26	465.57	431.65
Net income—diluted / Diluted earnings per share	330.41	381.85	465.25	431.39
Cash dividends applicable to period / Dividends per share	95.00	105.00	120.00	130.00
Net assets / Equity attributable to owners of the Company per share	2,755.29	3,053.29	3,405.20	3,722.90

Non-financial indicators

(unless specially noted, for Sawai Pharmaceutical)

	FY2013	FY2014	FY2015	FY2016
Sales volume (Billion tablets)	6.5	8.0	8.9	10.2
Production capacity (Billion tablets)	8.6	10.0	11.3	15.0
Number of new products launched	23	28	25	18
Number of patents held	14	19	21	23
Number of GMP audits	—	—	—	164
Number of employees (consolidated)	1,121	1,239	1,490	2,502
Number of female employees in managerial positions	9	10	10	11
Ratio of female employees in managerial positions (%)	4.8	5.2	4.5	4.5
Employee training expenses (Sawai Group) (Millions of yen)	65	83	90	111
Number of employees who have received training (Sawai Group)	323	418	596	660
Number of employees involved in production (Sawai Group)	350	414	628	1,612
Number of employees involved in R&D (Sawai Group)	167	185	209	230
Energy used (Sawai Group) (Crude oil conversion kl)	17,931	20,473	26,781	30,914

Notes 1. If there are differences in representation between Japanese GAAP and IFRS (voluntarily applied since fiscal 2017), the item is marked "Japan GAAP / IFRS."
 2. Capital expenditures are presented on a cash flow basis.
 3. As the Company split its common stock two for one on October 1, 2013, amounts per share for fiscal 2013 were recalculated to reflect the share split.
 4. Dividend per share in fiscal 2018 included our 90th anniversary commemorative dividend of ¥5.
 5. The U.S. business was classified as a non-continuing business in fiscal 2023. Fiscal 2022 and fiscal 2023 revenue, operating profit, and profit before tax are those for continuing businesses, excluding non-continuing business.

	IFRS →							
	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023
Net sales / Revenue	132,392	168,068	184,341	182,537	187,219	193,816	163,702	176,862
Cost of sales	80,548	98,628	109,442	109,037	114,785	127,164	113,450	122,543
Gross profit	51,844	69,440	74,899	73,500	72,434	66,652	50,252	54,319
Selling, general and administrative expenses/ Selling, general and administrative expenses (including research and development expenses)	28,497	47,264	49,051	46,862	53,820	71,103	34,754	35,433
Operating income / Operating profit (loss)	22,943	22,209	25,798	26,793	18,888	(35,888)	16,054	18,620
Profit before income taxes / Profit (loss) before tax	22,757	20,251	25,666	26,497	18,460	(36,214)	15,850	18,262
Profit attributable to owners of parent / Profit (loss) attributable to owners of the Company	17,969	14,017	19,376	19,279	12,340	(28,269)	12,667	13,695
Research and development (R&D) expenses	7,238	14,533	16,671	13,487	13,883	24,413	12,509	12,189
Capital expenditures	18,839	16,807	10,709	18,173	21,124	23,344	27,141	24,649
Depreciation and amortization	8,520	14,239	16,280	17,954	18,291	17,045	17,683	18,055
Total assets	225,609	358,453	372,889	384,814	393,341	349,502	364,165	382,024
Inventories	61,924	65,217	63,449	75,460	79,120	85,853	101,805	100,002
Total current liabilities	57,668	74,579	72,826	82,715	80,452	88,840	85,154	93,618
Total long-term liabilities / Total non-current liabilities	26,704	81,433	76,861	68,413	72,139	60,579	66,272	70,375
Net assets/Total equity	141,237	202,441	223,204	233,686	240,750	200,083	212,738	218,030
Net cash provided by operating activities/Cash flows from operating activities	23,270	28,472	42,923	30,256	31,857	34,310	13,026	23,149
Net cash used in investing activities/Cash flows from investing activities	(18,827)	(127,900)	(16,820)	(18,173)	(21,794)	(30,395)	(27,134)	(23,112)
Net cash provided by (used in) financing activities/Cash flows from financing activities	(6,761)	108,597	(9,513)	(12,747)	(11,991)	(11,262)	(1,267)	2,363
Cash and cash equivalents at end of year/Cash and cash equivalents at the end of the year	30,771	39,992	57,067	56,082	54,269	47,717	33,076	26,368
Ratio of R&D expenses to sales/Ratio of research and development expenses to revenue	5.5	8.6	9.0	7.4	7.4	12.6	7.6	6.9
Return on equity/Return on equity attributable to owners of the Company	13.4	8.7	10.2	9.4	5.8	(13.8)	6.5	6.6
Shareholders' equity to total assets/ Ratio of equity attributable to owners of the Company to total assets	62.6	50.6	53.4	54.6	55.5	54.4	55.4	55.7
Net income—basic / Basic earnings per share	487.38	360.49	442.62	440.37	281.80	(645.53)	289.25	312.67
Net income—diluted / Diluted earnings per share	487.08	360.26	442.32	440.00	281.51	(645.53)	288.60	311.79
Cash dividends applicable to period / Dividends per share	130.00	130.00	135.00	130.00	130.00	130.00	130.00	130.00
Net assets / Equity attributable to owners of the Company per share	3,830.84	4,143.15	4,551.50	4,796.40	4,984.51	4,340.32	4,604.67	4,854.96
Total assets	10.2	10.6	11.9	12.4	13.3	14.8	15.0	15.7
Production capacity (Billion tablets)	15.0	15.5	15.5	15.5	15.5	15.5	15.5	18.5
Number of new products launched	18	43	33	12	44	32	23	10
Number of patents held	23	26	31	36	37	42	45	53
Number of GMP audits	164	100	110	133	124	141	153	92
Number of employees (consolidated)	2,502	3,252	3,131	3,066	3,003	2,968	3,393	3,482
Number of female employees in managerial positions	11	14	15	15	15	17	18	22
Ratio of female employees in managerial positions (%)	4.5	5.5	6.0	6.1	5.8	6.6	6.9	9.9
Employee training expenses (Sawai Group) (Millions of yen)	111	128	87	62	45	63	88	92
Number of employees who have received training (Sawai Group)	660	579	654	600	4,038	2,840	4,034	3,795
Number of employees involved in production (Sawai Group)	1,612	1,749	1,687	1,644	1,607	1,636	2,015	2,097
Number of employees involved in R&D (Sawai Group)	230	246	257	251	246	253	295	297
Energy used (Sawai Group) (Crude oil conversion kl)	30,914	31,948	32,336	31,015	30,130	30,452	40,628	36,955